Healthcare Equipment and Supplies
Company Overview of HyperBranch Medical Technology, Inc.
HyperBranch Medical Technology, Inc., a medical device company, develops and markets products primarily for the traumatic or surgically induced wound market. It offers OcuSeal, a liquid ocular bandage for direct application on the surface of the eye to form an ocular bandage, thereby covering an opening in the eye and providing an immediate protective barrier; and Adherus Dural Sealant, which is used as an aid in dural repair in cranial and spinal surgeries, such as the treatment of intracranial aneurysms, tumors, and spinal disc disease. The company also provides Adherus Hernia Mesh Fixation, a device used as a replacement for tacks, staples, sutures, and 'O' rings in hernia repair procedur...
800-12 Capitola Drive
Durham, NC 27713-4410
Founded in 2003
Key Executives for HyperBranch Medical Technology, Inc.
Chief Executive Officer, Chief Operations Officer and Director
Co-Founder and Chief Scientific Officer
Medical Director and Member of Advisory Board
Compensation as of Fiscal Year 2016.
HyperBranch Medical Technology, Inc. Key Developments
HyperBranch Medical Technology, Inc. Wins Decision against Integra LifeSciences
Oct 12 16
HyperBranch Medical Technology, Inc. announced that it has defeated a motion by Integra LifeSciences to preliminarily enjoin HyperBranch from selling its Adherus AutoSpray Dural Sealant product. The Court’s opinion relied, in part, on evidence that “unquestionably shows that [Integra’s] DuraSeal’s applicator was associated with significant problems; the [Adherus] AutoSpray product’s applicator did not have such problems.” HyperBranch began selling Adherus AutoSpray Dural Sealant in the United States in July 2015 after receiving FDA approval. In September 2015, Integra sued HyperBranch for alleged patent infringement in the U.S. District Court for the District of Delaware. Integra also filed a motion seeking a preliminary injunction to prevent HyperBranch from selling Adherus AutoSpray Dural Sealant during the pendency of the lawsuit. On September 29, 2016, Chief Judge Leonard P. Stark adopted the Report and Recommendation of Magistrate Judge Christopher J. Burke and denied Integra’s motion. Rejecting Integra’s argument that it would suffer irreparable harm as a result of HyperBranch’s alleged patent infringement, the Court found: The record is replete with compelling evidence that the AutoSpray product is an attractive choice over DuraSeal due to a feature that undisputedly has nothing to do with the asserted patents—its applicator. This evidence unquestionably shows that: DuraSeal’s applicator was associated with significant problems; the AutoSpray product’s applicator did not have such problems; and this would be an important reason why physicians and hospitals would choose the AutoSpray product over the DuraSeal product. The Court also found that the public interest favors keeping Adherus AutoSpray Dural Sealant on the market during the pendency of the litigation. Citing testimony from three neurosurgeons with a combined 93+ years of experience, who “each expresse[d] a clear preference for the AutoSpray product,” along with documents from Integra that were “rife with references to the AutoSpray product’s improved applicator [and] to unresolved problems with DuraSeal,” the Court provided its rationale: there are only two FDA-approved dural sealant products for cranial procedures that are available in the United States market-Integra’s product and HyperBranch’s product; the products’ use has a real effect on the health of patients who have undergone serious surgical procedures; the record indicates that at least some number of physicians prefer HyperBranch’s product to Integra’s product (and does not contain much, if any, evidence regarding surgeons who prefer the DuraSeal product over the AutoSpray product); and the record suggests that the DuraSeal product has deficiencies that the AutoSpray product does not suffer from. The lawsuit will continue, with a trial scheduled to begin on April 16, 2018. In responding to the complaint, HyperBranch has denied Integra’s infringement allegations, asserted various defenses, including invalidity of the patents at issue, and requested an award of its attorneys’ fees and other litigation costs. HyperBranch intends to continue to defend itself vigorously against Integra’s claims and is confident that it will prevail on the merits.
Integra LifeSciences Holdings Corporation Files Lawsuit Against HyperBranch Medical Technology, Inc
Sep 15 15
On September 15, 2015, Integra LifeSciences Holdings Corporation announced that the company filed a lawsuit in the U.S. District Court for the District of Delaware against HyperBranch Medical Technology, Inc. The lawsuit alleges that HyperBranch's Adherus Autospray Dural Sealant, Adherus Dural Sealant, and Adherus Spinal Sealant infringe patents that the Company licenses from Incept LLC. The lawsuit contends that U.S. Patents 7,009,034; 7,592,418; 7,332,566; 6,566,406; 8,003,705; and 8,535,705 are infringed by HyperBranch's Adherus products. The lawsuit asks the court to enjoin HyperBranch from continuing to make, sell, and offer to sell the Adherus products and to grant treble damages for willful infringement.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|